Market Cap: $41.24M
AT
Aldeyra The
ALDX
NASDAQUSD
Market Cap: $41.24M
Aldeyra Therapeutics (Ticker: ALDX) focuses on its dry eye disease candidate reproxalap as it seeks feedback from the FDA following three complete response letters (CRLs) questioning the efficacy of t…
Aldeyra Therapeutics Faces Legal Scrutiny Amid FDA Setbacks Aldeyra Therapeutics, Inc. is currently at the center of an investigation by the Rosen Law Firm, which is exploring potential securities cla…
Aldeyra Therapeutics Under scrutiny: FDA Response Triggers Legal Investigations Aldeyra Therapeutics, a biopharmaceutical company focused on developing innovative therapies for ocular conditions, face…
Aldeyra Therapeutics Faces Regulatory Hurdles for Dry Eye Treatment Aldeyra Therapeutics encounters a significant setback as the FDA issues a Complete Response Letter (CRL) regarding its New Drug Appl…
Aldeyra Therapeutics Faces Regulatory Hurdle in Pursuit of Reproxalap Approval Aldeyra Therapeutics is currently navigating a significant setback after receiving a Complete Response Letter (CRL) from…
Aldeyra Therapeutics: Pioneering Innovations in the Biotech Landscape Aldeyra Therapeutics, a prominent player in the biotechnology industry, currently stands at the forefront of innovation, particula…
Aldeyra Therapeutics: Riding the Wave of Biotech Momentum Aldeyra Therapeutics stands at the forefront of a shifting landscape within the biotechnology sector, characterized by recent momentum-driven…
Aldeyra Therapeutics: Pioneering Innovative Therapies in Immune-Mediated and Metabolic Diseases Aldeyra Therapeutics, Inc. stands at the forefront of biotechnology, driving advancements in the treatme…
### Aldeyra Therapeutics Advances Innovative Approaches to Treat Immune-Mediated Diseases Aldeyra Therapeutics, Inc., a biotechnology firm focused on innovative therapies for immune-mediated and metab…
Aldeyra Therapeutics Advances Dry Eye Treatment with FDA Review Acceptance Aldeyra Therapeutics, Inc. announces a significant milestone as the U.S. Food and Drug Administration (FDA) accepts its resub…
Aldeyra Therapeutics Advances in Dry Eye Disease Treatment with FDA Review Acceptance Aldeyra Therapeutics, Inc. makes significant strides in the ophthalmology sector as the U.S. Food and Drug Adminis…
Aldeyra Therapeutics Showcases Innovative Approach to Drug Development at Upcoming Healthcare Conference Aldeyra Therapeutics, Inc., a biotechnology firm dedicated to advancing therapies for immune-me…
Aldeyra Therapeutics Advances Retina Research at Upcoming Symposium Aldeyra Therapeutics, Inc., a biotechnology firm specializing in innovative therapies for immune-mediated and metabolic diseases, is…
Aldeyra Therapeutics Advances Retina Research with Upcoming Presentation Aldeyra Therapeutics, Inc., a biotechnology company dedicated to pioneering therapies for immune-mediated and metabolic disease…